|1.||Guan, Zhonghong: 24 articles (05/2011 - 04/2006)|
|2.||Kaplan, Steven A: 16 articles (05/2014 - 12/2005)|
|3.||Bavendam, Tamara: 16 articles (11/2012 - 07/2005)|
|4.||Wang, Joseph T: 13 articles (11/2010 - 04/2006)|
|5.||Rovner, Eric S: 10 articles (01/2010 - 01/2004)|
|6.||Carlsson, Martin: 9 articles (05/2011 - 11/2006)|
|7.||Khullar, Vik: 8 articles (01/2012 - 03/2004)|
|8.||Jonas, U: 8 articles (06/2010 - 05/2000)|
|9.||Sun, Franklin: 7 articles (05/2014 - 11/2008)|
|10.||Brodsky, Marina: 7 articles (11/2010 - 10/2007)|
|1.||Overactive Urinary Bladder (Overactive Bladder)
06/01/2006 - "We evaluated the efficacy of tolterodine extended release (ER) for patients' most bothersome overactive bladder (OAB) symptom in a primary care setting. "
01/01/2004 - "Based on the low frequency of adverse events, the absence of unexpected adverse events and the very low frequency of serious adverse events, we conclude that tolterodine is a well tolerated treatment for overactive bladder in adults, in whom it should be considered as first-line therapy."
04/01/2001 - "There was an improvement in voiding diary variables in all treatment groups after 2 weeks of treatment, although the efficacy was greatest in those taking 1 mg and 2 mg. Pharmacokinetic findings were consistent with dose linearity over the range 0.5-2 mg. The results support the use of 1 mg twice daily as the optimal dose of tolterodine for treating children aged 5-10 years with an overactive bladder."
05/01/2005 - "Favorable safety, tolerability and efficacy of once-daily tolterodine ER was maintained over 12 months in a Japanese overactive bladder patient population."
02/01/2003 - "A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder."
01/01/2006 - "In addition, TDOXY was similar to tolterodine, and it produced a significant improvement in the number of urinary incontinence episodes, complete continence, and urodynamic and quality of life parameters compared with placebo. "
01/01/2012 - "Parameter estimates included utilities of improved urinary incontinence (0.92) and continued urinary incontinence (0.73), reduction in quality of life from side effects (5%), cost of percutaneous tibial nerve stimulation per session ($203) and cost of tolterodine ER per month ($150). "
10/01/2013 - "A total of six randomized clinical trials and 11 other studies of tolterodine in children with urinary incontinence were included in the present systematic review. "
01/01/2009 - "Previous studies demonstrate that tolterodine extended release (ER) significantly improves urgency urinary incontinence (UUI) episodes. "
07/01/2007 - "This is a quasi-experimental naturalistic, longitudinal, open and not controlled study made during 24 weeks with before-after analysis on 60 urgent or mixed urinary incontinence patients treated with physic therapy and tolterodine. "
|3.||Urge Urinary Incontinence (Urge Incontinence)
04/01/2002 - "After 1 week, tolterodine ER 4 mg had produced a significant improvement in all efficacy variables in both groups of patients (P < 0.01); 72% of the maximum effect on urge incontinence was observed in both groups; and 84.7% of drug-naive patients and 83.6% of previously treated patients perceived a benefit from treatment. "
10/01/2001 - "The advent of a new extended-release (ER) capsule formulation of tolterodine (4 mg) for convenient once-daily treatment builds upon these findings, with significantly improved efficacy for reducing urge incontinence episodes and a lower frequency of dry mouth relative to the existing IR tablet (2 mg b.i.d.). "
09/01/2003 - "Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone."
10/01/2001 - "A single trial found tolterodine extended-release 4 mg/day to have improved efficacy for decreasing urge incontinence episodes along with lower frequency of dry mouth vs. immediate-release tolterodine 2 mg bid. "
08/01/2004 - "The efficacy of tolterodine ER in reducing urge incontinence episodes was unaffected by the presence of stress incontinence. "
|4.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
09/01/2012 - "Re: The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign prostatic hyperplasia."
01/01/2012 - "Re: The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign prostatic hyperplasia."
04/01/2014 - "Seventy patients over 55 years of age who underwent transurethral resection of the prostate owing to benign prostatic hyperplasia were randomly assigned to receive either 2 mg of tolterodine twice daily (treatment group) or matched placebo during a 1-month study period. "
04/01/2011 - "To evaluate the efficacy and safety of Tolterodine Tartrate combined with the alpha-receptor blocker in the treatment of benign prostatic hyperplasia with detrusor overactivity (BPH-DO). "
04/01/2011 - "[Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity]."
01/01/2014 - "Tolterodine ER resulted effective in reducing frequency urgency and nocturia and urinary leakage in male patients with OAB/storage LUTS. "
01/01/2007 - "Episodes of urgency, incontinence, daytime frequency and nocturia and responses to the patient perception of bladder condition scale, the urgency perception scale, and visual analog scales of limitations in daily life and of treatment satisfaction were evaluated in 3,824 OAB patients at baseline and during 9 months treatment with tolterodine ER (4 mg q.d.) in an open-label, observational study. "
10/01/2007 - "Although women taking tolterodine ER 4 mg had a consistently greater increase in mean voided volume/void and consistent decreases in incontinence episodes/24 h, urgency episodes/24 h and episodes of nocturia/24 h, this was not statistically significant. "
06/01/1999 - "According to micturition charts, urinary frequency, nocturia, and leakage episodes decreased significantly after tolterodine treatment, whereas average urine volume per day and average voided volume did not change significantly. "
06/01/1999 - "The patients were contacted by telephone 1 week after visit 2. Tolterodine was increased to 2 mg bid if the patient had incomplete improvement at either the initial phone call or during visit 3. Evaluation criteria were daily micturition charts including urinary frequency, nocturia, leakage episodes, average urine volume per day, and average voided volume. "
|2.||quinuclidin- 3'- yl- 1- phenyl- 1,2,3,4- tetrahydroisoquinoline- 2- carboxylate monosuccinate (solifenacin)
|6.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
|1.||Drug Therapy (Chemotherapy)
|5.||Prostatectomy (Retropubic Prostatectomy)